TP53 and breast carcinoma: We evaluated the expression of p53, p21 and HER-2 protein expression by immunohistochemistry (IHC) before and after neoadjuvant docetaxel plus epirubicin in locally advanced breast cancer patients and their relationship with clinical response and outcome.